Overview
Flow processes for pharmaceutical purpose gain increasing importance, and their development meets the guidelines of the regulatory agencies U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Advantages are that the desired product quality can be more easily ensured and that numbering up of flow modules enables an elegant increase of the production scale without facing scale up concerns. Examples in this field are related to chemo- and biocatalytic reactions, e.g., the current ONE-FLOW project.
